Volume 3.18 | May 18

Prostate Cell News 3.18 May 18, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter

Reactive OxygenSpecies-Mediated Apoptotic Cell Death in Prostate Cancer LNCaP Cells Induced by Biosurfactant Stabilized CdS Quantum Dots
Researchers investigated the possible mechanisms of apoptosis induced by biosurfactant stabilized cadmium sulfide (CdS) quantum dots in human prostate cancer LNCaP cells. [Biomaterials] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Expression of Inhibitor of DNA-Binding Proteins Is Regulated by the Bcl-3 Proto-Oncogene in Prostate Cancer
Researchers suggested that inactivation of B-cell leukemia 3 (Bcl-3) may lead to sensitization of cancer cells to chemotherapeutic drug-induced apoptosis, thus implying a potential therapeutic strategy in prostate cancer treatment.
[Oncogene] Abstract

Evidence for Efficacy of New HSP 90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Investigators evaluated the biological actions of two new synthetic heat shock protein 90 (Hsp90) inhibitors in prostate cancer cell lines and in an ex vivo culture model of human prostate cancer. [Clin Cancer Res] Abstract

Differential Regulation of Androgen Receptor by PIM-1 Kinases via Phosphorylation-Dependent Recruitment of Distinct Ubiquitin E3 Ligases
Scientists reported that two PIM-1 kinase isoforms which are upregulated during prostate cancer progression, modulate androgen receptor stability and transcriptional activity. [J Biol Chem ] Full Article

A Competitive Inhibitor that Reduces Recruitment of Androgen Receptor to Androgen Responsive Genes
To identify novel inhibitors of androgen receptor (AR) transactivation that block growth of prostate cancer cells, a luciferase-based high throughput screen of approximately 160,000 small molecules was performed in cells stably expressing AR and a prostate-specific antigen-luciferase reporter.
[J Biol Chem] Full Article

Telomere and Microtubule Targeting in Treatment-Sensitive and Treatment-Resistant Human Prostate Cancer Cells
Scientists evaluated the relative efficacy of targeting telomeres and microtubules in taxane-sensitive, taxane-resistant, androgen-sensitive and androgen-insensitive prostate cancer cells. [Mol Pharmacol] Full Article

Constitutive and Treatment-Induced CXCL8-Signaling Selectively Modulates the Efficacy of Anti-Metabolite Therapeutics in Metastatic Prostate Cancer
Investigators characterized the effect of anti-metabolites on inducing CXCL8 signaling and determined whether the constitutive and/or drug-induced CXCL8 signaling in metastatic prostate cancer cells modulates their sensitivity to this class of agent. [PLoS One] Full Article

Piperlongumine Induces Rapid Depletion of the Androgen Receptor in Human Prostate Cancer Cells
Researchers investigated the functional impact of piperlongumine on androgen receptor expression in prostate cancer cells. [Prostate] Abstract

Uptake and Antitumoral Effects of Iodine and 6-Iodolactone in Differentiated and Undifferentiated Human Prostate Cancer Cell Lines
Investigators determined the uptake of iodide and iodine, as well as the antiproliferative and apoptotic effects of 6-iodolactone and both forms of iodine in human prostate cells lines. [Prostate] Abstract

Targeted Therapy with Fatty Acid Synthase Inhibitors in a Human Prostate Carcinoma LNCaP/Tk-Luc-Bearing Animal Model
Researchers used C75 and small interfering RNA targeted at fatty acid synthase to mediate the endogenous fatty acid metabolism in LNCaP human prostate cancer cells stably expressing herpes simplex virus type 1 thymidine kinase (HSV1-tk) and luciferase (luc) reporter genes. [Prostate Cancer Prostatic Dis] Abstract


Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer
To better characterize the metabolic effects of androgen deprivation therapy, researchers measured changes in plasma metabolomic profile at baseline and after the first three months of therapy. [Clin Cancer Res]

Outcome Predictors of Radical Prostatectomy followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease
Researchers performed subset analysis of a prospective trial including 550 consecutive patients with preoperative high risk prostate cancer. [J Urology] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.


Revised Patient Access Scheme and More Information Allow National Institute for Health and Clinical Excellence  to Recommend Abiraterone for Prostate Cancer
National Institute for Health and Clinical Excellence has issued new draft guidance recommending the use of abiraterone in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer. [National Institute for Health and Clinical Excellence] Press Release

GTx Announces Removal of Full Clinical Hold by FDA for Capesaris® in Advanced Prostate Cancer
GTx, Inc. announced that the Food and Drug Administration (FDA) removed its Full Clinical Hold on the company’s Investigational New Drug application for Capesaris®. GTx plans to initiate the Phase II open label clinical study of 75 men with metastatic castration resistant prostate cancer. [GTx, Inc.] Press Release

Cancer Experts Detail Treatments Using TrueBeam System to Reduce Number of Treatment Sessions and Take Better Account of Motion
European cancer experts have reported their progress with promising new radiosurgical techniques for treating cancer and other conditions using new linear accelerator technology from Varian Medical Systems. [Varian Medical Systems] Press Release


A Global Standard for Peer Review
After winning the strong backing of the White House, Subra Suresh convened a meeting of 47 leaders of research funding agencies from 44 countries. At the conclusion of closed-door sessions, the group will issue the first-ever global statement on the principles of merit review. [National Science Foundation, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Select Biosciences – Stem Cells & Bioprocessing Europe
June 27-28, 2012 
London, United Kingdom 

Visit our events page to see a complete list of events in the prostate cell community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Fellow – Prostate Research (Baylor College of Medicine)

Postdoctoral Fellow/Associate Research Scientist – Prostate Cancer (Columbia University Medical Center)

Recruit Top Talent:
Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us